[ { "id": 1581, "name": "Sigma Genetics", "slug": "sigma-genetics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/3d163f0758d535d9b800f2a88bdefffc73c5bbe2.png", "website": "http://www.sigmagenetics.com", "all_locations": "Seattle, WA, USA", "long_description": "Sigma Genetics develops devices that can deliver DNA, RNA, and other charged molecules into cells by using magnetic fields. When compared to conventional electroporation, this technique has several key advantages, which include: the absence of arcing, the ability to scale, and the benefit of being non-invasive for in vivo applications. This platform technology can be applied to a wide range of applications- cell therapies, cancer drug delivery, DNA vaccines, biopharma manufacturing, and cosmetics.", "one_liner": "Sigma Genetics is a biotechnology company that is building…", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1492902064, "tags": [ "Biotech", "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2017", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/sigma-genetics", "api": "https://yc-oss.github.io/api/batches/winter-2017/sigma-genetics.json" }, { "id": 1696, "name": "Forever Labs", "slug": "forever-labs", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/2551f858875b49e48688473a8dad17ee8425d618.png", "website": "https://foreverlabs.com", "all_locations": "Ann Arbor, MI, USA", "long_description": "Forever Labs collects and stores adult stem cells, and develops therapies based upon stem cell rejuvenation.", "one_liner": "We bank your stem cells to help you live healthier, longer.", "team_size": 12, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1495941669, "tags": [ "Anti-Aging" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2017", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/forever-labs", "api": "https://yc-oss.github.io/api/batches/summer-2017/forever-labs.json" }, { "id": 1767, "name": "Nectome", "slug": "nectome", "former_names": [], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "https://nectome.com/", "all_locations": "South San Francisco, CA, USA", "long_description": "Nectome is a neuroscience startup that aims to preserve the brain and keep all its memories intact.\r\n\r\nThe company is building the next generation of tools to preserve the connectome. The connectome is all the connections called synapses between neurons in the brain. Researchers from the company is now learning to manipulate individual memories, building advanced brain prosthetics, and reverse-engineering the brain.", "one_liner": "Building a way to preserve long-term memories.", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1509602625, "tags": [ "Neurotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2018", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/nectome", "api": "https://yc-oss.github.io/api/batches/winter-2018/nectome.json" }, { "id": 1768, "name": "Tradewind BioScience", "slug": "tradewind-bioscience", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/f5d93a10e6cabf940fdedbb063ff7b383002367d.png", "website": "https://www.tradewindbio.com", "all_locations": "San Francisco, CA, USA", "long_description": "Our lead candidate is a multifaceted attack antibody for ovarian cancer. Our approach enables targeting primary cancer cells directly, alongside enabling the immune system's natural anti-cancer function, all with one therapeutic antibody.", "one_liner": "Tradewind translates scientific insight into innovative ways of…", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1509642227, "tags": [], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2018", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/tradewind-bioscience", "api": "https://yc-oss.github.io/api/batches/winter-2018/tradewind-bioscience.json" }, { "id": 1773, "name": "Persephone Biosciences", "slug": "persephone-biosciences", "former_names": [ "Persephone Biome" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/23a03009ea76f97d455fc7ac751ee2643dbe4591.png", "website": "http://persephonebiosciences.com/", "all_locations": "San Diego, CA, USA", "long_description": "Persephone Biome develops live biotherapeutic products to modulate the metabolism of gut microbes, for applications in disease prevention and cure. We take a unique engineering approach using systems and synthetic biology to understand the complexities of the microbiome.", "one_liner": "We are using the gut microbiome to end cancer. ", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1509678246, "tags": [ "AI-powered Drug Discovery", "COVID-19" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2018", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/persephone-biosciences", "api": "https://yc-oss.github.io/api/batches/winter-2018/persephone-biosciences.json" }, { "id": 1775, "name": "Reverie Labs", "slug": "reverie-labs", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/c167c3874ed6d5b52b8c339d61851123a4540f2c.png", "website": "http://www.reverielabs.com", "all_locations": "Cambridge, MA, USA", "long_description": "Reverie Labs is engineering next-generation, brain-penetrant cancer therapies.\r\n", "one_liner": " Engineering next-generation, brain-penetrant cancer therapies.", "team_size": 29, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1509678248, "tags": [ "AI-powered Drug Discovery", "Machine Learning", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2018", "status": "Inactive", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/reverie-labs", "api": "https://yc-oss.github.io/api/batches/winter-2018/reverie-labs.json" }, { "id": 1865, "name": "Mind Emulation Foundation", "slug": "mind-emulation-foundation", "former_names": [ "Connectomics Foundation" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/0dbc747704a44b3c663e381fc1c6222694e3d1a4.png", "website": "https://mindemulation.org/", "all_locations": "", "long_description": "", "one_liner": "", "team_size": 1, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1513047754, "tags": [], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": true, "batch": "Winter 2018", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "Unspecified" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/mind-emulation-foundation", "api": "https://yc-oss.github.io/api/batches/winter-2018/mind-emulation-foundation.json" }, { "id": 1931, "name": "Hepatx", "slug": "hepatx", "former_names": [ "Hepatx Corporation" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/de67131e3a59da3affe582ccd6f671eb18fb38f2.png", "website": "http://www.hepatx.com", "all_locations": "Palo Alto, CA, USA", "long_description": "Our vision is to provide regenerative medicine treatments that free patients from chronic liver disease and help usher in an era where diseased and damaged tissues can be repaired.", "one_liner": "Replacing organ transplant with an infusion", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1524801868, "tags": [ "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/hepatx", "api": "https://yc-oss.github.io/api/batches/summer-2018/hepatx.json" }, { "id": 2016, "name": "dNovo", "slug": "dnovo", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/22ea7b2ff1e1af9ded028f1c3a9d1ad91f17021f.png", "website": "http://dnovobio.com/", "all_locations": "San Jose, CA, USA", "long_description": "At dNovo, we are curing hair loss by creating new hair, de novo. We are doing this with cellular reprogramming technology that we pioneered at Stanford and Harvard. With this technology, we can take any patient derived cell, whether it be blood, skin or fat and reprogram (convert) them into medically relevant cell types. Our first objective is to cure hair loss by using our reprogramming technology to make new hair (patent pending). This is different from everything currently available on the market because the hair loss industry is focused on maintaining the hair that you already have, but no one is trying to produce NEW hair, de novo. After hair, we envision using our cellular reprogramming technique to make any cell, any tissue or any organ on demand to replace what is lost as we age.", "one_liner": "The cure for hair loss.", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1635867695, "tags": [ "Anti-Aging" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Inactive", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/dnovo", "api": "https://yc-oss.github.io/api/batches/summer-2018/dnovo.json" }, { "id": 2021, "name": "Perception Biosystems", "slug": "perception-biosystems", "former_names": [ "Reformer Therapeutics", "Perception Therapeutics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/6725a216e652408a9448418d0067920052e512a2.png", "website": "https://www.perception.bio", "all_locations": "Palo Alto, CA, USA", "long_description": "Perception Biosystems is democratizing gene therapy through lab automation. Our mission is to accelerate the clinical translation of gene therapy by reinventing its manufacturing and development processes.\r\n\r\nWe're building a robotic lab in the SF Bay Area to translate the large facilities, labor, and regulatory requirements of current gene therapy factories into automated flexible manufacturing systems and code. This enables us to produce gene therapies for use in human clinical trials an order of magnitude faster and cheaper than the current solution – opening up thousands of rare disease targets otherwise thought too rare to pursue.", "one_liner": "Democratizing gene therapy by reinventing its manufacturing and…", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1527048485, "tags": [ "Gene Therapy", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Inactive", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/perception-biosystems", "api": "https://yc-oss.github.io/api/batches/summer-2018/perception-biosystems.json" }, { "id": 2027, "name": "Dorian Therapeutics", "slug": "dorian-therapeutics", "former_names": [ "Dorian therapeutics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/e2ba869954327a53b835f8f98ae03cf923b67fa1.png", "website": "http://www.doriantherapeutics.com", "all_locations": "San Carlos, CA, USA", "long_description": "", "one_liner": "New therapeutics to rejuvenate tissue and treat age-related diseases ", "team_size": 8, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1527534657, "tags": [ "Anti-Aging", "Biotech", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Acquired", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/dorian-therapeutics", "api": "https://yc-oss.github.io/api/batches/summer-2018/dorian-therapeutics.json" }, { "id": 2028, "name": "Rejuvenation Technologies Inc.", "slug": "rejuvenation-technologies-inc", "former_names": [ "Rejuvenation Technologies Inc.", "Rejuvenation Technologies" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/8570f907143e200c57848585eb12a16271d3643f.png", "website": "https://www.rejuvenationtech.com/", "all_locations": "San Francisco, CA, USA", "long_description": "Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Extends mouse lifespan by equivalent of 10 years in humans. Reverses 5-10 years of telomere shortening with one dose in one day. Preclinical efficacy in 4 organ systems including immune system. Entering clinical stage. CEO is Subject #1 in longevity trial. 50+ granted patents, 7 patent families. FDA INTERACT cleared. Raising $10M seed extension ($2M+ wired) to fund 3 investigator-initiated trials. Readouts in Q3 2027. $6.8B in comparable mRNA-LNP M&A in last 12 months. ", "one_liner": "mRNA therapeutics to extend healthspan entering clinical trials", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1527534662, "tags": [ "Anti-Aging", "Gene Therapy", "Nanomedicine" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/rejuvenation-technologies-inc", "api": "https://yc-oss.github.io/api/batches/summer-2018/rejuvenation-technologies-inc.json" }, { "id": 2029, "name": "Circumvent", "slug": "circumvent", "former_names": [ "Circumvent Pharmaceuticals" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/b5fd725fe8e2cac76ed87eacf3161d3f37da8f61.png", "website": "https://www.circumventpharmaceuticals.com/", "all_locations": "", "long_description": "", "one_liner": "Utilizing monogenic disorders to inform and solve highly complex…", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1527534673, "tags": [ "Neurotechnology", "Biotech", "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "Unspecified" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/circumvent", "api": "https://yc-oss.github.io/api/batches/summer-2018/circumvent.json" }, { "id": 2031, "name": "Gerostate Alpha", "slug": "gerostate-alpha", "former_names": [ "Gerostate𝝰" ], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "http://www.gerostatealpha.com", "all_locations": "Novato, CA, USA", "long_description": "", "one_liner": "Developing novel therapeutics for aging and chronic disease", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1527980791, "tags": [ "Biotech", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Inactive", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/gerostate-alpha", "api": "https://yc-oss.github.io/api/batches/summer-2018/gerostate-alpha.json" }, { "id": 11979, "name": "LEAH Labs", "slug": "leah-labs", "former_names": [ "Lifengine Animal Health Laboratories", "Incorporated" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/6907f0370b96042be3d0036ddc25c34015a02b50.png", "website": "http://www.leahlabs.com", "all_locations": "Minneapolis, MN, USA", "long_description": "LEAH Labs is building living therapies for pets first, and their people next. We're first focused on CAR-T cell therapy for dogs with B cell lymphoma, the naturally occurring clinical analog of human non-Hodgkin's lymphoma. CAR-T cells are curative in humans, and our early results are showing the same - we're inducing remissions in pets with late stage lymphomas. Our virus-free gene editing platform allows us to engineer a dose of CAR-T cell therapy for ~$500, and brings the promise of a curative outcome. Given our safety and efficacy data to date, we believe this product could be used by general practice veterinarians, meaning we have thousands of customers all across the USA who typically treat with palliative care or refer cancer patients to specialty oncologists. Our CAR-T cell platform is regulated by the USDA, not the FDA, affording us a cost effective \"full stack\" to iterate and innovate on CAR-T cell therapy from a hypothesis through clinical validation. ", "one_liner": "Living therapies for pets first, and their people next", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1541131379, "tags": [ "CRISPR", "Cell Therapy", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2019", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/leah-labs", "api": "https://yc-oss.github.io/api/batches/winter-2019/leah-labs.json" }, { "id": 12011, "name": "ResistanceBio", "slug": "viosera-therapeutics", "former_names": [ "Viosera Therapeutics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/85eb1576c695e918b9450d568294b56f42f0f7e0.png", "website": "http://www.resistance.bio", "all_locations": "Menlo Park, CA, USA; Overland, MO, USA", "long_description": "", "one_liner": "We solve drug resistance for cancer", "team_size": 15, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1541478882, "tags": [ "AI-powered Drug Discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2019", "status": "Inactive", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/viosera-therapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2019/viosera-therapeutics.json" }, { "id": 12046, "name": "Excepgen", "slug": "excepgen", "former_names": [ "Excepgen INC" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/307d19bc5c381fd52d2955c58bdf163b34fac3b7.png", "website": "http://www.excepgen.com", "all_locations": "San Francisco, CA, USA", "long_description": "", "one_liner": "", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1541567035, "tags": [ "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2019", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/excepgen", "api": "https://yc-oss.github.io/api/batches/winter-2019/excepgen.json" }, { "id": 12056, "name": "Intact Therapeutics", "slug": "intact-therapeutics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/3cd29a4a99693702d0e100b9a7d5fbcf89df7edc.png", "website": "http://www.intacttherapeutics.com", "all_locations": "San Francisco, CA, USA; Los Altos, CA, USA", "long_description": "Intatct is developing an advanced materials platform to improve the way drugs are delivered and absorbed in the digestive tract. Our vision is to improve the treatment of a wide range of gastrointestinal disorders that are currently underserved.", "one_liner": "Smart gels for local drug delivery to the gut", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1541617440, "tags": [ "Drug Delivery", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2019", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/intact-therapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2019/intact-therapeutics.json" }, { "id": 12210, "name": "Endpoint Health", "slug": "endpoint-health", "former_names": [ "Endpoint Health", "Inc." ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/91f103c5ea8ba96047f1ef891154ca0f0c8dea47.png", "website": "https://endpointhealth.com/", "all_locations": "San Francisco, CA, USA; Palo Alto, CA, USA; Remote", "long_description": "Endpoint Health is on a mission to address urgent needs in immune-driven critical and chronic illnesses by delivering therapies that are personalized to each patient’s biology. We built Endpoint Health from the ground up to develop and commercialize therapeutics and therapy-guiding tests, to ensure that every patient receives personalized treatment that will dramatically improve their outcomes. Our vision is a world in which all patients have effective, personalized treatment, because therapies are targeted to the right patient at the right time.", "one_liner": "Precision-first therapies", "team_size": 23, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1594656273, "tags": [], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2019", "status": "Inactive", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/endpoint-health", "api": "https://yc-oss.github.io/api/batches/winter-2019/endpoint-health.json" }, { "id": 12286, "name": "1910", "slug": "1910", "former_names": [ "1910 Genetics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/5e2b26953347f453a160b7941e16df81a78374b3.png", "website": "http://1910.ai", "all_locations": "Boston, MA, USA", "long_description": "We are the only AI-native biotech pioneering small and large molecule therapeutics discovery by integrating massive multimodal data, frontier AI models, and high-throughput lab automation into an infrastructure for AI-enabled drug discovery.", "one_liner": "Multimodal AI Platform for Modality Agnostic Drug Discovery™", "team_size": 20, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1616511668, "tags": [ "AI-powered Drug Discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2019", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/1910", "api": "https://yc-oss.github.io/api/batches/winter-2019/1910.json" }, { "id": 12355, "name": "YourChoice Therapeutics", "slug": "yourchoice-therapeutics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/5ee153812f550aed3a1d617decff16839415814f.png", "website": "http://ychoicetx.com", "all_locations": "San Francisco, CA, USA; Berkeley, CA, USA", "long_description": "YourChoice Therapeutics is revolutionizing the global contraceptive market. Our vision is to develop non-hormonal contraceptives to provide both women and men with birth control options that lack the associated risks of hormone-based options but are equally effective. Traditionally, it has been the women’s financial and health burden to have a contraceptive in place. Our first goal is therefore to bring a novel non-hormonal, on-demand and low cost female contraceptive to the market that will substantially improve their quality of life and well-being. Our second goal is to develop the first ever non-surgical and highly effective non-hormonal contraceptive for men. Currently, male contraception is limited to two main options – vasectomy or condoms. Having such options available to both women and men will globally allow for much better family planning, reduce the number of unwanted pregnancies including abortions and therefore reduce costs and ensure contraceptive health and well-being.", "one_liner": "YourChoice therapeutics is revolutionizing the contraceptive market…", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1545442492, "tags": [ "Health Tech", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2019", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/yourchoice-therapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2019/yourchoice-therapeutics.json" }, { "id": 12579, "name": "Encepheal Therapeutics", "slug": "encepheal-therapeutics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/e2254c6db4aca1a94f4c379b3299c517203af457.png", "website": "http://www.encepheal.com", "all_locations": "Winston-Salem, NC, USA", "long_description": "EncepHeal is developing medications to treat substance abuse. Our first product is a small molecule therapeutic for stimulants like cocaine and methamphetamine, of which there are no FDA approved treatments.\r\n\r\nOur small molecule technology are atypical inhibitors of the dopamine transporter. Cocaine itself is an inhibitor of the same transporter. Directly reducing craving or positive reinforcement is a successful treatment strategy for addiction. Methadone or buprenorphine (Suboxone) are key examples of this for opioid use disorder. However, these types of medications can be addictive themselves. This has been a major hurdle for medication development for cocaine addiction and has led to many leaders in the addiction space to abandon the dopamine transporter as a target. At EncepHeal, we believe that the dopamine transporter should not be abandoned and instead focusing on fixing the abuse liability problem. Therefore with our partners at the National Institutes of Health, we have shown that these new, allosteric modulators at the dopamine transporter do not display addictive tendencies in animal models. They are also effective at curbing cocaine addiction. \r\n\r\nOur management team has two co-founders, Omeed Rahimi and Aaron Lazarus, as well as an experienced addiction pharmacologist as their research officer. The team has an advisory board with entrepreneurial and addiction drug development experience as well as expert partners at the National Institute on Drug Abuse, a subset of the NIH, and Wake Forest.\r\n\r\nOur team has had success in raising non-dilutive funding and has expertise with SBIR/STTR grants. We are looking for help in better connecting with the biotech/pharmaceutical industry.\r\n\r\n", "one_liner": "EncepHeal develops medications to treat substance abuse, starting…", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1556165074, "tags": [ "Therapeutics", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2019", "status": "Inactive", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/encepheal-therapeutics", "api": "https://yc-oss.github.io/api/batches/summer-2019/encepheal-therapeutics.json" }, { "id": 12614, "name": "GEn1E Lifesciences", "slug": "gen1e-lifesciences", "former_names": [ "Gen1E Lifesciences", "Inc.", "Gen1E Lifesciences" ], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "https://www.gen1e.com", "all_locations": "Palo Alto, CA, USA", "long_description": "GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). \r\n \r\nGEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Our AI platform enables tremendous pace and capital efficiency as demonstrated by our progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry.\r\n \r\nWith ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need.\r\n \r\nThe team at GEn1E has decades of experience in drug development and machine learning. We graduated from YCombinator and Stanford-StartX in late 2019. We are based in Palo Alto, CA.", "one_liner": "AI platform accelerating therapies for rare & inflammatory diseases.", "team_size": null, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1651188804, "tags": [ "Artificial Intelligence", "Biotech", "Healthcare", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2019", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/gen1e-lifesciences", "api": "https://yc-oss.github.io/api/batches/summer-2019/gen1e-lifesciences.json" }, { "id": 12861, "name": "Asher Bio", "slug": "asher-bio", "former_names": [ "Asher Biotherapeutics", "Asher Biotherapeutics", "Asher Bio", "Asher Biotherapeutics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/6ebff96239c6b3bdc84c6e935bf7862294c380cd.png", "website": "https://www.asherbio.com/", "all_locations": "San Francisco, CA, USA; San Carlos, CA, USA", "long_description": "Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases. \r\n\r\nAsher Bio is backed by Third Rock Ventures and is located in South San Francisco.", "one_liner": "We build better immunotherapies", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1559270475, "tags": [ "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2019", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": true, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/asher-bio", "api": "https://yc-oss.github.io/api/batches/summer-2019/asher-bio.json" }, { "id": 13217, "name": "Altay Therapeutics", "slug": "altay-therapeutics", "former_names": [ "Altay Therapeutics Inc" ], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "http://www.altaytherapeutics.com", "all_locations": "San Francisco, CA, USA; South San Francisco, CA, USA", "long_description": "Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. \r\n\r\nWith a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. \r\n\r\nWe know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue. \r\n\r\nWith our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022. \r\n", "one_liner": "Altay develops disease-modifying therapies targeting transcription…", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1583513059, "tags": [ "AI-powered Drug Discovery", "Biotech", "Therapeutics", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2020", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/altay-therapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2020/altay-therapeutics.json" }, { "id": 13434, "name": "OpenBiome", "slug": "openbiome", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/25c85b99f2ca8aeb8dec9ea8945defebc1753fb2.png", "website": "http://openbiome.org", "all_locations": "Cambridge, MA, USA", "long_description": "We are a nonprofit stool bank, expanding safe access to fecal transplants and catalyzing research on the human microbiome.", "one_liner": "A nonprofit stool bank enabling access to fecal transplants.", "team_size": 70, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1597673599, "tags": [ "Nonprofit" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": true, "batch": "Winter 2020", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/openbiome", "api": "https://yc-oss.github.io/api/batches/winter-2020/openbiome.json" }, { "id": 13601, "name": "Equator Therapeutics", "slug": "equator-therapeutics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/2c3115ee7654ff0be36a7d764f8dd7f98b178d2e.png", "website": "https://equatortherapeutics.com/", "all_locations": "San Francisco, CA, USA", "long_description": "We are developing a drug to increase metabolism and burn calories without exercise.\r\n\r\nObesity and type 2 diabetes have reached epidemic proportions. There are 2.2B overweight people and 500M people with type 2 diabetes worldwide, and these numbers increase drastically every year. Existing drugs are not effective enough to reverse the trend. Our drug can solve this problem, because it addresses the root cause of metabolic disorders – the imbalance between caloric intake and expenditure.\r\n\r\nOur drug will target mitochondria – the powerhouse of the cell – to generate heat. This approach has been proven to fully reverse obesity and type 2 diabetes in animals. However, therapeutic application for humans was impossible, because mitochondrial heat production could only be induced by highly artificial methods with side effects. This changed after our recent breakthrough discovery of the protein that mitochondria naturally use to generate heat. We have developed a unique high-throughput drug discovery platform to identify compounds that selectively activate this target protein, without side effects.\r\n\r\nFor decades people have wanted a drug that burns calories like exercise does. We are realizing this dream at Equator Therapeutics.", "one_liner": "We are developing a drug to burn calories and increase metabolism…", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1584215124, "tags": [ "Biotech", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2020", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/equator-therapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2020/equator-therapeutics.json" }, { "id": 13672, "name": "Ochre Bio", "slug": "ochre-bio", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/d80993cda53fffe2cfd91762d630c27dc21561bf.png", "website": "https://www.ochre-bio.com/", "all_locations": "Oxford, England, United Kingdom", "long_description": "Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases.", "one_liner": "RNA medicines for liver diseases", "team_size": 50, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1583988274, "tags": [ "Biotech", "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2020", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United Kingdom", "Europe", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/ochre-bio", "api": "https://yc-oss.github.io/api/batches/winter-2020/ochre-bio.json" }, { "id": 21881, "name": "Kernal Biologics", "slug": "kernal-biologics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/1534fd5c3c1e4705596c793a4a59a28da388bacf.png", "website": "https://www.kernalbio.com/", "all_locations": "Boston, MA, USA", "long_description": "Kernal Bio is a biotech company pioneering mRNA 2.0 immunotherapies. We leverage selective mRNA-LNP technology to treat cancer and autoimmune diseases with precision, ensuring targeted cell delivery and minimal off-target effects. Our KR-402 program achieves over 90% delivery efficiency with T-cell-targeted LNPs, enabling direct CAR-T programming within the body and resulting in B-cell depletion within a week.\r\n \r\nKernal Bio is led by a team with experience from MIT, Harvard, Merck, and BMS, boasting three FDA-approved therapies and over 120 patents. Based in Cambridge, MA, we are backed by Hummingbird Ventures, Amgen Ventures, HBM, and even NASA.\r\n\r\nWith roots at MIT, Harvard and Biopharma, Kernal’s management team has deep expertise in mRNA therapeutics space. CEO Yusuf Erkul, M.D., M.B.A. is a successful drug hunter whose research at Merck enabled an FDA-approved drug for ovarian cancer. President Burak Yilmaz, M.S., previously founded Sentegen, a thriving synthetic biology company which commercializes synthetic DNA, RNA, and diagnostic kits for genetic and infectious diseases. Sr. VP of R&D Manfred Kraus is a leader in immuno-oncology, who was most recently Scientific Sr. Director at Bristol-Myers Squibb (BMS). ", "one_liner": "Kernal is creating mRNA 2.0 therapies that work in specific cells", "team_size": 20, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1599762607, "tags": [ "Artificial Intelligence", "Biotech", "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2020", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/kernal-biologics", "api": "https://yc-oss.github.io/api/batches/summer-2020/kernal-biologics.json" }, { "id": 22045, "name": "Nephrogen", "slug": "nephrogen", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ce4f8b04c9fefa06f0088d04f45b91af1e3fe8aa.png", "website": "http://www.nephrogenbiotech.com", "all_locations": "New York, NY, USA", "long_description": "Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. \r\n\r\nNephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.", "one_liner": "Curative genetic medicines for kidney diseases", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1660881251, "tags": [ "Gene Therapy", "CRISPR", "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2020", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/nephrogen", "api": "https://yc-oss.github.io/api/batches/summer-2020/nephrogen.json" }, { "id": 22617, "name": "Serna Bio", "slug": "serna-bio", "former_names": [ "Ladder Therapeutics (LTX)" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/e5c345ecf4dc0bf6d96b3cb2f1e7485d78c1449d.png", "website": "http://serna.bio", "all_locations": "Ontario, CA, USA; Remote", "long_description": "Serna Bio is developing small molecules to modulate RNA function, unlocking the potential to treat diseases driven by biology intractable by other modalities. \r\n", "one_liner": "Genetic Medicine with Small Molecules ", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1659537090, "tags": [ "Biotech", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2021", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/serna-bio", "api": "https://yc-oss.github.io/api/batches/winter-2021/serna-bio.json" }, { "id": 22764, "name": "Valink Therapeutics", "slug": "valink-therapeutics", "former_names": [ "SpyCombinator", "LiliumX" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/4fdbac90b07fa4233736c11be944db20adb49e3b.png", "website": "https://www.valinktx.com/", "all_locations": "Boston, MA, USA", "long_description": "Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.", "one_liner": "Discovering bispecific antibody drug-conjugates (BsADC) against cancer", "team_size": 15, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1614618602, "tags": [ "Biotech", "Therapeutics", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2021", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/valink-therapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2021/valink-therapeutics.json" }, { "id": 23190, "name": "Biodock", "slug": "biodock", "former_names": [ "Biodock AI" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ef18ff7a47b6ccba783538bb34567deafd6e5a0f.png", "website": "https://www.biodock.ai", "all_locations": "Austin, TX, USA", "long_description": "Biodock's cloud platform accelerates microscopy analysis, automating months of microscopy analysis and infrastructure to minutes with our end-to-end AI architecture. Scientists enjoy auto-scaling storage, GPU compute, and 30-50% more accurate analysis.\r\n\r\nWe're building an amazing experience to translate microscopy images to therapeutic insights for academic and enterprise scientists.", "one_liner": "Cloud AI microscopy automation", "team_size": 8, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1614650681, "tags": [ "Artificial Intelligence", "Deep Learning", "SaaS" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Winter 2021", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/biodock", "api": "https://yc-oss.github.io/api/batches/winter-2021/biodock.json" }, { "id": 23263, "name": "Entelexo Biotherapeutics", "slug": "entelexo-biotherapeutics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/2ef38251e4060b4827ae3ce45f0e73e1f6f1cb2d.png", "website": "https://www.entelexo.com/", "all_locations": "Irvine, CA, USA", "long_description": "Entelexo is creating modern treatments for immune-mediated diseases, such as psoriasis, using novel engineered exosome technology.", "one_liner": "Creating a New Class of Drugs to Address Incurable Autoimmune Diseases", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1614964227, "tags": [ "Biotech" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2021", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/entelexo-biotherapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2021/entelexo-biotherapeutics.json" }, { "id": 23522, "name": "Nuntius Therapeutics", "slug": "nuntius-therapeutics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/490dca692522bd958768d197eafc08f9ea77c8fb.png", "website": "http://www.nuntiustx.com", "all_locations": "London, England, United Kingdom", "long_description": "", "one_liner": "Cell-specific genetic medicines", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1614621461, "tags": [ "Gene Therapy", "Nanomedicine" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2021", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United Kingdom", "Europe", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/nuntius-therapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2021/nuntius-therapeutics.json" }, { "id": 23610, "name": "PipeBio", "slug": "pipebio", "former_names": [ "Pipe|bio" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/b6fb87df991642ec6fcea487e6c1e54683c1319f.png", "website": "https://pipebio.com", "all_locations": "Aarhus, Denmark; Remote", "long_description": "Pipe|bio is the bioinformatics cloud for antibody / peptide screening & drug development.\r\n\r\nWe enable scientists to analyze and manage massive amounts of DNA sequencing data themselves without the need for bioinformaticians or programmers. The software is highly visual and enables you to overlay and filter information from different sources across your organization; be it assay data, sequence data or other process metadata. Insights from past results can be used to guide new experiments and they get better as you upload more and more data. Team leads get oversight and these capabilities combined empower organizations to find better drugs, faster.\r\n\r\nWe believe that science moves faster when scientists can curate and analyse their own data.", "one_liner": "PipeBio is a SaaS bioinformatics platform to develop antibody drugs.", "team_size": 10, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1614718514, "tags": [ "AI-powered Drug Discovery", "Machine Learning", "SaaS" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2021", "status": "Acquired", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "Denmark", "Europe", "Remote", "Fully Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/pipebio", "api": "https://yc-oss.github.io/api/batches/winter-2021/pipebio.json" }, { "id": 23783, "name": "Promakhos Therapeutics", "slug": "promakhos-therapeutics", "former_names": [ "Promakhos Therapeutics Inc." ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/2bf583e0e272b341a471dca1a79bbef1feb19285.png", "website": "https://www.promakhos.com/", "all_locations": "Boston, MA, USA", "long_description": "We are building a platform of bacterial molecules to awaken our body’s innate ability to control inflammation and heal. Our first indication is Crohn’s Disease, which affects over 500,000 Americans at an annual cost of $10B. After Crohn's disease, we are going for type 1 Diabetes and Multiple Sclerosis.", "one_liner": "A therapeutics platform for curing inflammatory disorders", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1626969479, "tags": [ "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/promakhos-therapeutics", "api": "https://yc-oss.github.io/api/batches/summer-2021/promakhos-therapeutics.json" }, { "id": 24008, "name": "Catena Biosciences", "slug": "catena-biosciences", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/f1d289877a701c3b0826470c1e3ff501de0e4759.png", "website": "https://www.catenabiosciences.com/", "all_locations": "San Francisco, CA, USA; Berkeley, CA, USA", "long_description": "Catena’s technology lets us attach any two proteins together using an enzyme and the native amino acids tyrosine and cysteine within target proteins. It is a true platform technology because it enables the joining of any two soluble proteins together with minimal engineering and without restrictions due to protein size or complexity. Our work has already been used to modify cancer specific antibodies, CRISPR proteins and even cell surfaces. Our ability to produce modular protein therapeutics in a fraction of the time allows for true library creation across the therapeutics spectrum from oncology, vaccines, inflammatory disease and beyond.\r\n", "one_liner": "Using protein coupling to build new therapies", "team_size": 7, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1624576033, "tags": [ "Biotech", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/catena-biosciences", "api": "https://yc-oss.github.io/api/batches/summer-2021/catena-biosciences.json" }, { "id": 24443, "name": "Inflow", "slug": "inflow", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/63a830ded6794d91b1e36abf5ae5bb0cb246fff3.png", "website": "https://getinflow.io/", "all_locations": "London, England, United Kingdom; New York, NY, USA", "long_description": "Inflow is a self-help app for people to manage their ADHD. They provide support through psychoeducation, habit development, and community.", "one_liner": "A self-help app for people to manage their ADHD.", "team_size": 20, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1630088307, "tags": [ "Mental Health Tech", "Consumer Health Services" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Acquired", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United Kingdom", "United States of America", "Europe", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/inflow", "api": "https://yc-oss.github.io/api/batches/summer-2021/inflow.json" }, { "id": 24601, "name": "Humane Genomics", "slug": "humane-genomics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/47e90007a89a7dd904342a1da559cc31eb51d9a3.png", "website": "https://humanegenomics.com", "all_locations": "New York City, NY, USA; New York, NY, USA", "long_description": "Humane Genomics has developed a platform to engineer cancer killing viruses. We have taken a first principles approach to design and make oncolytic viral therapies. Using a highly lytic RNA virus engineered with \"2 factor authentication\" (using selective infection and selective replication) they have an on-target to off-target kill ratio > 1000. We are working on our first indication, pediatric liver cancer (hepatoblastoma), with our partners at Texas Children's Hospital, who are world leading experts. We have in vivo (mouse) data showing safety and currently developing efficacy data and are showing 50% reduction in tumor volume. ", "one_liner": "A platform to make artificial viruses as cancer therapeutics.", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1626893262, "tags": [ "Hard Tech", "Synthetic Biology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/humane-genomics", "api": "https://yc-oss.github.io/api/batches/summer-2021/humane-genomics.json" }, { "id": 24705, "name": "Sensible Biotechnologies", "slug": "sensible-biotechnologies", "former_names": [ "Genbiotics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/45d14c57e3b4e2739c65c0bb84a511608548ffa2.png", "website": "https://sensible.bio", "all_locations": "Oxford, England, United Kingdom", "long_description": "The future of mRNA therapeutics is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible enables the next generation of mRNA medicines by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA in a scalable and cost-effective way.", "one_liner": "Unlocking the next generation of mRNA medicines", "team_size": 24, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1680519323, "tags": [ "Synthetic Biology", "Biotech", "Manufacturing", "Therapeutics", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United Kingdom", "Europe", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/sensible-biotechnologies", "api": "https://yc-oss.github.io/api/batches/summer-2021/sensible-biotechnologies.json" }, { "id": 24795, "name": "SFA Therapeutics", "slug": "sfa-therapeutics-inc", "former_names": [ "SFA Therapeutics, Inc." ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/5873834b208e59808a81e6f7b65403be4dd9fc78.png", "website": "https://sfatherapeutics.com/", "all_locations": "Philadelphia, PA, USA", "long_description": "SFA Therapeutics is creating therapeutically-tailored oral drugs that regulate the immune system; with a focus on autoimmune diseases and cancers that originate from chronic inflammation. There are over 300 million patients who suffer from autoimmune diseases. Our treatment is designed to block the root cause of many of these chronic inflammatory diseases, with safe oral drugs. We have strong clinical data from a phase 1b clinical trial in psoriasis, and human data in pancreatic cancer, uveitis and NASH. we have a total of 9 drugs in our pipeline and 15 patents.", "one_liner": "Regulating the immune system to block cancer & autoimmune diseases", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1624038758, "tags": [ "AI-powered Drug Discovery", "Anti-Aging", "Biotech", "Health & Wellness", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": true, "app_answers": true, "question_answers": true, "url": "https://www.ycombinator.com/companies/sfa-therapeutics-inc", "api": "https://yc-oss.github.io/api/batches/summer-2021/sfa-therapeutics-inc.json" }, { "id": 25151, "name": "Keylika", "slug": "keylika", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/bd12fc4dc5d053441f31a9c528579e0d16f3449e.png", "website": "https://www.keylika.com", "all_locations": "Walnut Creek, CA, USA", "long_description": "Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes. \r\n\r\nOur first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market.", "one_liner": "Redefining the Standard of Care for Iron Deficiency Anemia", "team_size": 1, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1658519436, "tags": [ "AI-powered Drug Discovery", "Medical Devices", "Drug Delivery", "Nanotechnology", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2022", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": true, "app_answers": true, "question_answers": false, "url": "https://www.ycombinator.com/companies/keylika", "api": "https://yc-oss.github.io/api/batches/summer-2022/keylika.json" }, { "id": 25331, "name": "Engage Bio", "slug": "engage-bio", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/e95b5dd7ee1a5f617dc0a83136e30199f883050a.png", "website": "http://engagebio.com", "all_locations": "San Francisco, CA, USA", "long_description": "Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine.\r\n \r\nIn 2026 Engage was acquired by Eli Lilly.", "one_liner": "Potent, durable, and redosable non-viral genetic medicines", "team_size": 10, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1647555290, "tags": [ "Synthetic Biology", "Biotech", "Healthcare", "Therapeutics", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2022", "status": "Acquired", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/engage-bio", "api": "https://yc-oss.github.io/api/batches/winter-2022/engage-bio.json" }, { "id": 25449, "name": "Alixia", "slug": "alixia", "former_names": [ "Guided Clarity" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ff4093c59629c7638e73b36eb069911e0922c140.png", "website": "http://www.alixia.com", "all_locations": "San Francisco, CA, USA", "long_description": "Our compounds disrupt the metabolic and\r\ninflammatory triggers in both cancer and quasi-cancerous\r\ncells in the tumor microenvironment. By impacting multiple cell\r\ntypes, we are enabling effective, lasting cancer treatments.", "one_liner": "Targeting the Tumor Ecosystem to address cancer drug resistance.", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1648247483, "tags": [ "Biotech", "Therapeutics", "Drug discovery", "Oncology", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2022", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/alixia", "api": "https://yc-oss.github.io/api/batches/winter-2022/alixia.json" }, { "id": 26122, "name": "Origami Therapeutics, Inc.", "slug": "origami-therapeutics-inc", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ec01151ea9fbf839d64b9d2a17dedc03fb322eeb.png", "website": "http://origamitherapeutics.com", "all_locations": "San Diego, CA, USA", "long_description": "Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our proprietary human disease models developed to select the small molecules with the best chance of clinical success. Our first indication is Huntington’s disease, a debilitating, progressive and ultimately fatal disorder caused by a genetic mutation. We have already identified small molecules that reduce the toxic mutated protein, suppress mutant protein-induced toxicities in human disease neurons and get into the brain. We anticipate that this approach will be broadly applicable to traditionally “undruggable” targets in other neurological diseases.", "one_liner": "Oral drugs to halt neurodegeneration", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1647386798, "tags": [ "Biotech", "Therapeutics", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2022", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/origami-therapeutics-inc", "api": "https://yc-oss.github.io/api/batches/winter-2022/origami-therapeutics-inc.json" }, { "id": 26427, "name": "Eugit Therapeutics", "slug": "eugit-therapeutics", "former_names": [ "EUGIT Tx", "EUGIT Therapeutics", "Eugit", "Eugit Therapeutics Inc" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/a88b74cc086730f852f068c605f2dcaa54b40a16.png", "website": "http://www.eugittx.com", "all_locations": "San Francisco, CA, USA; South San Francisco, CA, USA", "long_description": "Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years.\r\n\r\nCofounded by George Church (Harvard) and funded by Y Combinator (S22).", "one_liner": "Enabling Tissue Targeting of Therapies", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1656718658, "tags": [ "Cell Therapy", "Synthetic Biology", "Therapeutics", "Oncology", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2022", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/eugit-therapeutics", "api": "https://yc-oss.github.io/api/batches/summer-2022/eugit-therapeutics.json" }, { "id": 26734, "name": "Serinus Biosciences", "slug": "serinus-biosciences", "former_names": [ "Serinus" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/b6e7bac94ec8bfc7378ed11602bae7ea50215536.png", "website": "http://www.serinus.bio", "all_locations": "New York, NY, USA", "long_description": "Serinus Biosciences is tackling one of the toughest problems in cancer treatment: creating combination therapies to override treatment resistance. We leverage cutting edge technology to design a fully explainable AI platform primed with decades of system biology knowledge. Uniquely powered for biological inference, our AI engine uncovers how cancer cells evolve treatment resistance and identifies molecules to overcome resistance escape routes. We design combinations that are safer, more effective, and can get to patients quickly. Founded by MIT PhDs and supported by a scientific advisory board of top academics from the Broad Institute, Dana-Farber, and UCSD, Serinus is powered by Y Combinator and other top investors to revolutionize precision medicine.", "one_liner": "Combinations therapy by rational design", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1656454958, "tags": [ "Biotech", "Therapeutics", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2022", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/serinus-biosciences", "api": "https://yc-oss.github.io/api/batches/summer-2022/serinus-biosciences.json" }, { "id": 27168, "name": "Relevium Medical", "slug": "relevium-medical", "former_names": [ "Relevium", "ReleviumBio" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/fe3f53ef710ec5758d984168f33594337d5df8ae.png", "website": "https://relevium-medical.com/", "all_locations": "Galway, County Galway, Ireland", "long_description": "Relevium Medical is developing an injectable gel for knee osteoarthritis. Approximately half the population will be diagnosed with this pain and progressive disease.\r\nRight now, patients have to undergo not only repeat injections to control their pain, but also have to take strong oral medications. Because the disease is progressive and only gets worse over time, many patients end up on highly addictive, high-dose opioids. \r\nTo date, we have secured $3.7 million in non dilutive funding and completed preclinical testing. We demonstrated that our drug is safe, selectively blocks nerves that transmit pain, and provides pain relief that lasts four times as long. \r\nInsurance currently pays $770 per six-monthly treatment for knee osteoarthritis. With 5 million patients in the US, this represents a $7.7 Bn market opportunity.\r\nThis platform biotherapeutic can also be used to treat other joints affects by osteoarthritis such as the hip and ankle, where the same problems exist in treatment care. ", "one_liner": "Platform injectable gel based therapeutic for osteoarthritis", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1653661401, "tags": [ "Medical Devices", "Healthcare", "Therapeutics", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2022", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "Ireland", "Europe" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/relevium-medical", "api": "https://yc-oss.github.io/api/batches/summer-2022/relevium-medical.json" }, { "id": 27263, "name": "Guardian Bio", "slug": "guardian-bio", "former_names": [ "GuardianBio" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/686bc0e4b74ba3953559c1bb8515351010e84b61.png", "website": "http://www.guardian-bio.com", "all_locations": "Boston, MA, USA", "long_description": "Your immune system is your body’s best weapon and defense against cancer. It is only when it is overcome that cancer develops into full blown disease. Dendritic cells sit at the helm of the immune system, directing and dictating immune responses. Data has shown dendritic cells are often dysfunctional in cancer patients, and that this dysfunction is a bottleneck for other therapies. \r\n\r\nGuardian Bio’s approach is focused on creating a dendritic cell-based product which drives anti-tumor activity through activating the killers of the immune system AND training them against multiple cancer targets. We take stem cells from cancer patients, turn them into specific therapeutic dendritic cells specially trained against that patient’s tumor, and re-introduce them back into the body. \r\n\r\nOur therapeutic dendritic cells revitalize the killers of the immune system and give them the kickstart they need to fight - and win - against cancer.", "one_liner": "Dendritic cell-based platform for cancer therapy ", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1657134176, "tags": [ "Biotech", "Healthcare", "Therapeutics", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2022", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/guardian-bio", "api": "https://yc-oss.github.io/api/batches/summer-2022/guardian-bio.json" }, { "id": 28205, "name": "Modulari-T", "slug": "modulari-t", "former_names": [ "Modulari-T Biosciences" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/cdfde836f1d168c7ec0299ab6b4daf90d112f929.png", "website": "https://modularit.bio", "all_locations": "Montreal, QC, Canada; San Francisco, CA, USA", "long_description": "Cell and gene therapy promises to one day cure any disease; Modulari-T’s Platform produces the tools to fulfill that promise.\r\n\r\nModulari-T has designed a new family of synthetic genes that can reprogram cells to better sense their environment and modify their behavior accordingly. This can be used to engineer immune cells to efficiently recognize and kill cancer cells or to create stem cells able to regenerate any tissue.\r\n\r\nModulari-T looks to expand its technology to reach every area of cell therapy and become the platform of reference for cell engineering.", "one_liner": "We teach your immune system to attack and cure cancer", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1675126815, "tags": [ "Gene Therapy", "Cell Therapy", "Synthetic Biology", "Biotech", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2023", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "Canada", "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/modulari-t", "api": "https://yc-oss.github.io/api/batches/winter-2023/modulari-t.json" }, { "id": 29305, "name": "SynsoryBio", "slug": "synsorybio", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/e2b7538a15335c79e864ff7431e761c3feca0797.png", "website": "https://www.synsorybio.com/", "all_locations": "Boston, MA, USA", "long_description": "SynsoryBio is creating next generation, protein therapeutics that sense where they are in the body and only activate at diseased tissue. This technology platform has the potential to expand the therapeutic window of highly potent drugs and apply to many diseases such as cancer and autoimmune disorders.", "one_liner": "\"If-then\" conditional logic for protein drugs", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1707422039, "tags": [ "Synthetic Biology", "Biotech", "Therapeutics", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/synsorybio", "api": "https://yc-oss.github.io/api/batches/winter-2024/synsorybio.json" }, { "id": 29429, "name": "Velorum Therapeutics", "slug": "velorum-therapeutics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/f201fcf7f4408f2acdedabe7f9bef2baabec8369.png", "website": "https://www.velorumtx.com/", "all_locations": "San Francisco, CA, USA", "long_description": "Velorum Therapeutics is developing breakthrough medicines by unlocking the biology of heme.", "one_liner": "Breakthrough medicines unlocking the biology of heme", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1706719304, "tags": [ "Biotech", "Healthcare", "Therapeutics", "Drug discovery", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/velorum-therapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2024/velorum-therapeutics.json" }, { "id": 29470, "name": "Eris Biotech", "slug": "eris-biotech", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/b16bbab6bd8003573ebc3410a08531b90c3427fd.png", "website": "http://www.erisbio.com", "all_locations": "Lehi, UT, USA", "long_description": "We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma. ", "one_liner": "Our drugs engage the immune system to fight tumors", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1706246904, "tags": [ "Biotech", "Therapeutics", "Drug discovery", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/eris-biotech", "api": "https://yc-oss.github.io/api/batches/winter-2024/eris-biotech.json" }, { "id": 29475, "name": "Evolvere BioSciences", "slug": "evolvere-biosciences", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/dd3489b7e5a5f2d3f7cc49de65917a83134da0a3.png", "website": "https://www.evolverebiosciences.com/", "all_locations": "Oxford, England, United Kingdom", "long_description": "🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells. \r\n\r\n☠️ Current antibiotics stop working because bacteria evolve resistance to them. This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈. \r\n\r\n🧬 Our approach leverages co-evolutionary protein-protein interaction datasets combined with AI to forecast bacterial mutations and create ‘future-proof’ antibiotics, addressing antibiotic resistance before it develops. This changes the game for how frequently society will need to make new antibiotics and how long our new antibiotics will be able to treat patients 👩‍⚕️.\r\n\r\nWe are a team of biochemists and evolutionary biologists who met at the University of Oxford. ", "one_liner": "Making Next-Generation Antibiotics that Outpace Bacterial Evolution", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1723833827, "tags": [ "AI-powered Drug Discovery", "Artificial Intelligence", "Biotech", "Therapeutics", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United Kingdom", "Europe" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/evolvere-biosciences", "api": "https://yc-oss.github.io/api/batches/summer-2024/evolvere-biosciences.json" }, { "id": 29476, "name": "Junction Bioscience", "slug": "junction-bioscience", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/3c382f7f1170e4d96b382d69430f2fc2c9fffe94.png", "website": "https://www.junction.bio/", "all_locations": "New York City, NY, USA", "long_description": "Junction Bioscience is building an autonomous AI scientist to navigate the discovery of transformative medicines. Our scientific hypothesis engine iterates upon breakthrough chemistry from the laboratory to achieve clarity and control over the molecular basis of disease. We focus on the intersection of neuroinflammation and immunology where uncommon molecular insights position us to develop best-in-class therapies for millions of patients in need.", "one_liner": "AI Hypothesis Engine for Molecular Discovery", "team_size": 1, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1710785076, "tags": [], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/junction-bioscience", "api": "https://yc-oss.github.io/api/batches/winter-2024/junction-bioscience.json" }, { "id": 29485, "name": "Granza Bio", "slug": "granza-bio", "former_names": [ "Zyme Therapeutics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/e4fe5f43800f16c0ca16303f58b955037e3f2bc1.png", "website": "https://www.granzabio.com/", "all_locations": "San Francisco, CA, USA", "long_description": "Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunity. ", "one_liner": "Building programmable therapeutics for the immune system", "team_size": 7, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1709082658, "tags": [ "Synthetic Biology", "Biotech", "Healthcare", "Therapeutics", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/granza-bio", "api": "https://yc-oss.github.io/api/batches/winter-2024/granza-bio.json" }, { "id": 29527, "name": "ParcelBio", "slug": "parcelbio", "former_names": [ "Parcel Therapuetics", "Parcel Therapeutics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/74f762bd0f8856c1dbe4d716afa6585e44f03870.png", "website": "https://parcelbio.com/", "all_locations": "San Francisco, CA, USA", "long_description": "ParcelBio is engineering a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm™ platform uses novel RNA domains to enhance protein expression and extend activity, enabling therapies that reach the thresholds required for meaningful, and potentially curative, clinical outcomes. The company is advancing programs in autoimmune disease, oncology, and encoded protein therapeutics.", "one_liner": "Elevated mRNA for transformative medicines.", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1707343020, "tags": [ "Gene Therapy", "Synthetic Biology", "Biotech", "Therapeutics", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/parcelbio", "api": "https://yc-oss.github.io/api/batches/winter-2024/parcelbio.json" }, { "id": 29714, "name": "Kopra Bio", "slug": "kopra-bio", "former_names": [ "GlioTx" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/acdb0c2a3124d9e5717a63d0231af9b6f7447919.png", "website": "https://kopra.bio", "all_locations": "San Francisco, CA, USA", "long_description": "Kopra Bio makes genetically engineered viruses that teach your immune system to kill cancer using tech we developed at UCSF. We’re making the next Keytruda ($25B/yr cancer drug blockbuster) starting with the most aggressive form of brain cancer, glioblastoma. In the most challenging brain cancer model, we improve survival from 0% with the current FDA approved treatment to 90% with our treatment.", "one_liner": "Genetically engineered viruses that teach your immune system to kill…", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1724130421, "tags": [ "Gene Therapy", "Synthetic Biology", "Biotech", "Therapeutics", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/kopra-bio", "api": "https://yc-oss.github.io/api/batches/summer-2024/kopra-bio.json" }, { "id": 29959, "name": "Uncommon Therapeutics", "slug": "uncommon-therapeutics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/791a2a1e71f62bafa47311d3711d9cab4712eea4.png", "website": "https://uncommontherapeutics.com", "all_locations": "San Francisco, CA, USA", "long_description": "Our founder Noah, an experienced tech entrepreneur, was directly impacted by a severe genetic disease when his daughter was diagnosed with Rett Syndrome, a disease that afflicts 1 in 10,000 girls. Using an innovative polytherapy strategy, we’ve successfully improved her quality of life, and have designed new therapeutics that each could be worth billions and together could deliver a cure.", "one_liner": "A Disease Focused Biotech, Building Multiple Billion Dollar Drugs", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1740166772, "tags": [ "Gene Therapy", "CRISPR", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2025", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/uncommon-therapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2025/uncommon-therapeutics.json" }, { "id": 29986, "name": "Exin Therapeutics", "slug": "exin-therapeutics", "former_names": [ "EI Therapeutics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/61d9c34b51f9b98cbfdb92bc0014e3569c29b36c.png", "website": "https://www.exintherapeutics.com/", "all_locations": "San Francisco, CA, USA", "long_description": "We use AI and high-throughput mouse studies to discover therapeutics that modify neural activity in the brain. The initial focus is on epilepsies associated with autism and Parkinson’s disease with the potential to expand to any neurological disorder underlined by a dysfunction in neural activity. Our R&D is guided by AI models trained on high-density multimodal mouse data generated in-house.\r\n\r\nWe are 3 Oxford-trained neuroscientists supported by an experienced SAB from Harvard, Science Corp (ex-Neuralink), EPFL, Meta, and UCL.\r\n\r\nIn 1.5 months since landing in SF, we went from nothing to (1) opening and operating an animal lab in South SF, (2) obtaining a proof-of-concept in mice, (3) building a multimodal AI model that directs our screening approach and (4) submitting two provisional patents; all while utilizing less than 50% of our YC funding. \r\n", "one_liner": "AI drug discovery platform for neurotherapeutics", "team_size": 9, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1736839155, "tags": [ "Neurotechnology", "Biotech", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2025", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/exin-therapeutics", "api": "https://yc-oss.github.io/api/batches/winter-2025/exin-therapeutics.json" }, { "id": 30613, "name": "Blank Bio", "slug": "blank-bio", "former_names": [ "Orthrus Bio" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/7849a6bd6406353cb8f9f09c914d22bd1f4c0650.png", "website": "http://blank.bio/", "all_locations": "San Francisco, CA, USA", "long_description": "Blank Bio is an applied AI research lab focused on increasing the success rates of clinical trials. We do this by training RNA foundation models that learn the patterns that shape disease progression and patient response to treatment. We aim to help pharma make more informed decisions in clinical trials by capturing the biology that makes each patient’s tumour unique. \r\n\r\nWe’re a technical team of AI scientists and engineers from companies including Recursion, Deep Genomics, DeepMind, and Amazon, and institutions including Memorial Sloan Kettering Cancer Centre, Stanford, and the Vector Institute.", "one_liner": "RNA intelligence for precision medicine", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1754432955, "tags": [], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Summer 2025", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/blank-bio", "api": "https://yc-oss.github.io/api/batches/summer-2025/blank-bio.json" }, { "id": 30915, "name": "FinalDose", "slug": "finaldose", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/5910d81ebbfb17b7489c9613332140c02f40b7f4.png", "website": "https://finaldose.ai/", "all_locations": "London, England, United Kingdom", "long_description": "FinalDose is building the first programmable drug - a single smart drug molecule that you can insert any diseased genetic code and it can search and destroy cells upon DNA recognition. Unlocking 80% of undruggable targets today. Starting with all cancers.", "one_liner": "Programmable DNA drug destroying all cancers, unlocking 80% of targets", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1778543597, "tags": [ "Artificial Intelligence", "Gene Therapy", "Therapeutics", "Genetic Engineering" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Spring 2026", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United Kingdom", "Europe" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": false, "url": "https://www.ycombinator.com/companies/finaldose", "api": "https://yc-oss.github.io/api/batches/spring-2026/finaldose.json" } ]